Quantitative bioanalysis in the DMPK arena has traditionally been facilitated through the use of triple quadrupole mass spectrometers (offering both excellent selectivity and sensitivity when operated in SRM mode). High resolution mass spectrometers (HRMS) have largely been employed to perform qualitative analyses and have more recently found a niche in biopharmaceutical analysis. However, due to their superior mass resolution abilities, our laboratory is routinely using HRMS to overcome bioanalytical challenges facing our development portfolio of both small and large molecules. Several case studies will be presented.
What will you learn?
- The capabilities and limitations of HRMS in drug development; ability to develop validated methods
- How to use HRMS to overcome selectivity challenges
- Potential of HRMS for intact analysis of large molecules
Who may this interest?
Bioanalytical scientists working in drug discovery and development, small molecule DMPK and biopharmaceutical DMPK
Christopher A Evans serves as the departmental site head of Bioanalytical Sciences and Toxicokinetics at GlaxoSmithKline, guiding both site-based and CRO outsourced bioanalytical (mass spectrometry and ligand binding) as well as TK activities for small molecule, biopharmaceutical, and biomarker projects under various stages of drug development. He also serves on teams guiding DMPK activities for various clinical assets. Evans obtained a BS in chemistry from the University of Maryland at College Park (MD, USA) and a PhD in analytical chemistry from Purdue University (IN, USA) under the direction of R. Graham Cooks.
Click here to view the Q&A follow-up.
For a full list of other webinars available on Bioanalysis Zone please see here.